Novo Nordisk A/S $NVO Stock Bought by JCIC Asset Management Inc.

JCIC Asset Management Inc. increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 29.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 72,923 shares of the company’s stock after purchasing an additional 16,784 shares during the quarter. Novo Nordisk A/S makes up 1.1% of JCIC Asset Management Inc.’s investment portfolio, making the stock its 26th biggest holding. JCIC Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $2,765,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of NVO. Arrowstreet Capital Limited Partnership acquired a new position in Novo Nordisk A/S during the 1st quarter worth about $287,660,000. Maverick Capital Ltd. acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $76,444,000. Public Employees Retirement System of Ohio bought a new position in shares of Novo Nordisk A/S during the first quarter worth about $27,802,000. CORDA Investment Management LLC. bought a new position in shares of Novo Nordisk A/S during the first quarter worth about $15,322,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Novo Nordisk A/S by 2,414.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 297,881 shares of the company’s stock worth $14,280,000 after acquiring an additional 286,034 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

NVO stock opened at $42.21 on Thursday. The stock has a 50-day moving average price of $40.84 and a 200-day moving average price of $44.07. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. The firm has a market cap of $188.45 billion, a PE ratio of 10.32, a price-to-earnings-growth ratio of 1.36 and a beta of 0.70.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 58.61% and a net margin of 35.36%. The company had revenue of $11.98 billion for the quarter. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.42 earnings per share for the current year.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo beat analysts’ estimates for third-quarter earnings and revenue. Adjusted sales rose 4%, adjusted operating profit increased 27%, and obesity-drug sales climbed 22%. The company raised its full-year 2026 sales and operating-profit outlook. Reuters report on earnings and guidance
• Positive Sentiment: Wegovy pill sales exceeded Wall Street expectations, giving Novo a promising early foothold in the oral weight-loss drug market and helping drive the outlook upgrade. CEO Mike Doustdar said the launch had exceeded expectations. BioPharma Dive report on Wegovy pill sales
• Neutral Sentiment: Doustdar declined to provide 2027 guidance, leaving investors without a clear view of growth beyond this year. Novo’s CFO Karsten Munk Knudsen is also expected to leave the company. Article on earnings, outlook and 2027 guidance
• Negative Sentiment: Pricing pressure and weaker diabetes performance remain risks to growth, while impairment charges weighed on reported operating profit. Competition from Eli Lilly also remains a concern, especially as the oral obesity-drug market develops. Zacks analysis of earnings and risks

Analyst Ratings Changes

NVO has been the topic of a number of recent analyst reports. Cfra lowered Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price objective on the stock. in a research note on Tuesday, September 22nd. BMO Capital Markets set a $40.00 target price on shares of Novo Nordisk A/S and gave the company a “market perform” rating in a research report on Monday, October 12th. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, October 8th. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Five equities research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $59.44.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.